Previous studies have demonstrated that the PS model provided a better prognosis value than the AS model in individuals with breast cancer [3, 4, 6, 15], including the subgroup analysis for ER positive [5] and HER2 positive BCs [16]. This evidence concerns the gene ERBB2 and breast carcinoma.